- Product Details
Keywords
- raw material
- API
- anticancer
Quick Details
- ProName: Sunitinib Malate (CAS No.: 341031-54-7...
- CasNo: 439081-18-2
- Application: Anticancer Raw Material
- DeliveryTime: 7-12 days
- PackAge: Aluminum Foil Bag or Fiber Drum
- Port: Shenzhen
- ProductionCapacity: 100 Metric Ton/Month
- Purity: 99
- Transportation: EMS
- LimitNum: 100 Gram
Superiority
Sunitinib Malate (CAS No.: 341031-54-7)
Chemical Information
Product name:Sunitinib Malate
CAS No.:341031-54-7
Molecular formula: C22H27FN4O2.C4H6O5
Molecular weight: 532.56
Purity: 99%+
Product Specifications: Pharmaceutical Grade
MOQ(Minimum Order Quantity): 100g
Payment: L/C, T/T,
Shipment: EMS, DHL, FedEx, TNT
Brand: Newbio Pharm-Tech
Description
Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including c-KIT, FLT3 kinase, colony-stimulating factor 1 receptor and RET kinase. The IC50 of sunitinib is approximately 10-20 ng/ml to NB cell lines, which is within the clinically relevant human trough serum concentration (50-100 ng/ml).
Details
Sunitinib Malate (CAS No.: 341031-54-7)
Chemical Information
Product name:Sunitinib Malate
CAS No.:341031-54-7
Molecular formula: C22H27FN4O2.C4H6O5
Molecular weight: 532.56
Purity: 99%+
Product Specifications: Pharmaceutical Grade
MOQ(Minimum Order Quantity): 100g
Payment: L/C, T/T,
Shipment: EMS, DHL, FedEx, TNT
Brand: Newbio Pharm-Tech
Description
Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including c-KIT, FLT3 kinase, colony-stimulating factor 1 receptor and RET kinase. The IC50 of sunitinib is approximately 10-20 ng/ml to NB cell lines, which is within the clinically relevant human trough serum concentration (50-100 ng/ml).